
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences is supported by a differentiated scientific thesis: PMN310 is designed to selectively bind toxic amyloid-beta oligomers while sparing plaque, which could improve both efficacy and tolerability if the AβO hypothesis proves correct. The company’s PRECISE-AD Phase 1b interim data in 144 patients were encouraging, showing zero ARIA-E across all genotypes, placebo-like ARIA-H of 4.4%, and biomarker declines in pTau217 (-15%) and CSF MTBR-tau243 (-13.3%), while Phase 1a also showed dose-dependent exposure. Financially, the company reported a 2Q26 net loss of $11.7MM with $53.4MM in cash, and that balance was said to fund operations through 2027, supporting continued clinical execution ahead of the anticipated 1Q27 topline.
Bears say
ProMIS Neurosciences is viewed negatively because its lead program PMN310 remains a high-risk, unproven Alzheimer’s bet in a field where a closely related oligomer-targeting approach just failed in Ph2, raising doubts about whether selective Aβ oligomer binding can translate into meaningful clinical benefit. The company’s own risk profile is elevated by the uncertainty around the ongoing PRECISE-AD P1b study, where pooled biomarker analysis may dilute signal, while the cited DCF assumes only a 30% probability of approval, an 11.5% discount rate, and equity value of $255M with $100M in cash and 16.62M shares outstanding at the end of 2Q27. Beyond clinical risk, the stock faces financing and dilution pressure because later-stage Alzheimer’s development is large and costly, and PMN must still prove it can differentiate on efficacy and safety against approved, well-resourced competitors.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ProMIS Neurosciences Inc (PMN) Forecast
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares